Analyst Price Targets — RAPP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 24, 2026 10:32 am | — | Leerink Partners | $52.00 | $38.88 | TheFly | Rapport Therapeutics initiated with an Outperform at Leerink |
| May 21, 2026 11:46 am | — | BTIG | $65.00 | $35.72 | TheFly | Rapport Therapeutics price target raised to $65 from $53 at BTIG |
| May 18, 2026 10:56 pm | — | Truist Financial | $56.00 | $35.18 | TheFly | Rapport Therapeutics assumed with a Buy at Truist |
| April 10, 2026 9:40 am | Tiago Fauth | Raymond James | $66.00 | $34.12 | TheFly | Rapport Therapeutics initiated with a Strong Buy at Raymond James |
| March 9, 2026 1:49 pm | Kambiz Yazdi | BTIG | $47.00 | $29.97 | StreetInsider | BTIG Reiterates Buy Rating on Rapport Therapeutics (RAPP): "see the X-TOLE2 readout as having no readthrough" |
| February 2, 2026 10:58 am | Benjamin Burnett | Wells Fargo | $43.00 | $26.61 | TheFly | Rapport Therapeutics initiated with an Overweight at Wells Fargo |
| December 19, 2025 10:19 am | — | Wells Fargo | $51.00 | $29.64 | StreetInsider | Goldman Sachs Reiterates Buy Rating on Rapport Therapeutics (RAPP) |
| December 9, 2025 11:09 am | Douglas Tsao | H.C. Wainwright | $40.00 | $30.16 | TheFly | Rapport Therapeutics price target raised to $40 from $34 at H.C. Wainwright |
| September 16, 2025 10:11 am | Joon Lee | Truist Financial | $44.00 | $24.85 | TheFly | Rapport Therapeutics initiated with a Buy at Truist |
| July 2, 2024 4:51 am | Andrew Tsai | Jefferies | $35.00 | $25.44 | TheFly | Rapport Therapeutics initiated with a Buy at Jefferies |
Latest News for RAPP
Shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy
COO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on a weighted average price of $41.58 per share. This sale represented 6.2% of Gault's direct holdings, reducing her position from 159,914 to 149,914 shares.
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences. Jefferies Global…
Rapport Therapeutics, Inc. (RAPP) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.68 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RAPP.
U.S. House Trading
No House trades found for RAPP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.